Lv5
881 积分 2021-02-20 加入
Size-Dependent In Vivo Transport of Nanoparticles: Implications for Delivery, Targeting, and Clearance
6天前
已完结
Biologic degraders push forward in the clinic
7天前
已完结
Development of GE8820 for Selective and Rapid Removal of Pathogenic Autoantibodies in Primary Membranous Nephritis (PMN) and Other IgG4-Mediated Diseases
7天前
已完结
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models
25天前
已完结
The role of OX40 in cancer immunotherapy: A comprehensive review from mechanisms to clinical applications
25天前
已完结
Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial
1个月前
已完结
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study
1个月前
已完结
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
1个月前
已完结
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
1个月前
已完结
Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis
1个月前
已完结
皖公网安备34019202002308
